Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Zhejiang Provincial People's Hospital is the lead sponsor of 31 current clinical trials in our China register. 22 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Aspirin, Cilostazol and Fasudil Hydrochloride. The most-studied condition is Cerebral Small Vessel Diseases.

ClinicalTrials.gov trials by status

Recruiting2271%
Not yet open619%
By invitation310%

Trials by phase

Observational1342%
Phase 2516%
Not applicable516%
Phase 4310%
Phase 1/226%
Phase 326%
Phase EARLY_PHASE113%

Clinical trials sponsored by Zhejiang Provincial People's Hospital

31 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis NCT06979271 · ClinicalTrials.gov ↗ · Telitacicept, Treatment Compliance, Rheumatoid Arthritis	Observational	Recruiting	2025-06	China
Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis NCT07491016 · ClinicalTrials.gov ↗ · Telitacicept, Treatment Compliance, Rheumatoid Arthritis	Observational	Recruiting	2026-03	China
Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease NCT06431711 · ClinicalTrials.gov ↗ · Cerebral Small Vessel Diseases, Retinal Ischemia, Choroid; Injury	Observational	Recruiting	2024-04	China
An Exploratory Study on Gene Methylation Detection of Colorectal Cancer NCT07033156 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer), Adenoma Colon	Observational	Recruiting	2024-12	China
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis NCT06031610 · ClinicalTrials.gov ↗ · Carotid Artery Stenosis, Cerebral Small Vessel Diseases	Observational	Recruiting	2023-06	China
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC NCT05446467 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	2022-09	China
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 · ClinicalTrials.gov ↗ · NSCLC, SCLC, Colorectal Cancer Drug: Mirabegron	Phase 2	Recruiting	2024-07	China
Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia NCT06537115 · ClinicalTrials.gov ↗ · Sarcopenia	Phase 4	Recruiting	2024-06	China
Drug-induced Kidney Injury Model NCT06939387 · ClinicalTrials.gov ↗ · Acute Kidney Injury	Observational	Recruiting	2025-03	China
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study NCT07312422 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PD-L1, PD-1 Inhibitor Drugs: Folfirinox, Pucotenlimab	Phase 1/2	Recruiting	2025-09	China
Steroid Diabetes in Patients With Kidney Disease NCT06161701 · ClinicalTrials.gov ↗ · Nephrotic Syndrome	Observational	Recruiting	2024-01	China
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study) NCT06530732 · ClinicalTrials.gov ↗ · Alzheimer's Disease Drug: Lecanemab	Phase 3	Recruiting	2024-07	China
Radiomics-based Malnutrition for Cervical Cancer. NCT05709769 · ClinicalTrials.gov ↗ · Cervical Cancer, Malnutrition	Observational	Recruiting	2023-01	China
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer NCT06890858 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: Fasudil Hydrochloride	Phase 2	Recruiting	2025-04	China
Allogeneic WTX-212C in Advanced Solid Tumors NCT07556653 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase EARLY_PHASE1	Recruiting	2026-06	China
Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study) NCT06451887 · ClinicalTrials.gov ↗ · Endovascular Therapy, Brain Edema, Prediction Model	Observational	Recruiting	2024-04	China
An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease NCT06852352 · ClinicalTrials.gov ↗ · Alzheimer Disease, Parkinson Disease	Not applicable	Recruiting	2025-02	China
Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study NCT06164262 · ClinicalTrials.gov ↗ · Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior	Observational	Recruiting	2024-01	China
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds NCT06530537 · ClinicalTrials.gov ↗ · Cerebral Microbleeds, Stroke Drugs: Aspirin, Cilostazol	Phase 3	Recruiting	2024-07	China
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer NCT06722911 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable	Phase 2	Recruiting	2024-11	China
Efficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study NCT06888050 · ClinicalTrials.gov ↗ · New-onset Type 2 Diabetes Drug: Metformin	Phase 4	Recruiting	2025-04	China
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542 · ClinicalTrials.gov ↗ · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma Drugs: Sacituzumab tirumotecan, Tislelizumab	Not applicable	Recruiting	2025-07	China
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence NCT06939400 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme (GBM)	Observational	Not yet open	2025-06	China
Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer NCT06845098 · ClinicalTrials.gov ↗ · Thyroid Gland	Not applicable	Not yet open	2025-02	China
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC NCT06856278 · ClinicalTrials.gov ↗ · Anaplastic Throid Carcinoma	Phase 1/2	Not yet open	2025-02	China
The Effectiveness of Pharmaceutical Service for INPATDRP NCT06674512 · ClinicalTrials.gov ↗ · Drug Related Problem	Not applicable	Not yet open	2024-12	China
Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules NCT07340177 · ClinicalTrials.gov ↗ · Thyroid Nodules	Phase 4	Not yet open	2026-03	China
Spinal Cord Stimulation Combined With Motor Imagery Brain-Computer Interface for Chronic Post-Stroke Upper Limb Motor Dysfunction NCT07686822 · ClinicalTrials.gov ↗ · Chronic Stroke	Not applicable	Not yet open	2026-09	China
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. NCT07550972 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of the Head and Neck	Phase 2	By invitation	2026-05	China
Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia NCT07829276 · ClinicalTrials.gov ↗ · Malignant Tumor	Observational	By invitation	2026-11	China
Evaluation of Clinical Efficacy and Prognosis in Patients With Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT NCT06683872 · ClinicalTrials.gov ↗ · Hypertrophic Cardiomyopathy (HCM)	Observational	By invitation	2024-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Zhejiang Provincial People's Hospital trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Aspirin1 Cilostazol1 Fasudil Hydrochloride1 Folfirinox1 Lecanemab1 Metformin1 Mirabegron1 Pucotenlimab1 Sacituzumab tirumotecan1 Tislelizumab1

Conditions in Zhejiang Provincial People's Hospital trials

51 conditions

Cerebral Small Vessel Diseases3Telitacicept2Treatment Compliance2Rheumatoid Arthritis2Glioblastoma Multiforme (GBM)1Squamous Cell Carcinoma of the Head and Neck1Retinal Ischemia1Choroid; Injury1Thyroid Gland1CRC (Colorectal Cancer)1Adenoma Colon1Carotid Artery Stenosis1 Head and Neck Squamous Cell Carcinoma1 NSCLC1 SCLC1 Colorectal Cancer1 Pancreas Cancer1 Malignant Tumor1 Sarcopenia1 Acute Kidney Injury1 Pancreatic Cancer1PD-L11PD-1 Inhibitor1LDRT1

By trial register

Register	Trials	Recruiting
Clinical trials in China	31	22

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Cerebral Small Vessel Diseases

Sponsor	Trials
Dongzhimen Hospital, Beijing	2

Sponsors with the most current trials registered for this condition.

Questions about Zhejiang Provincial People's Hospital trials

How many clinical trials does Zhejiang Provincial People's Hospital sponsor?

Zhejiang Provincial People's Hospital is the lead sponsor of 31 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhejiang Provincial People's Hospital trials recruiting?

Yes. 22 of its 31 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhejiang Provincial People's Hospital testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Aspirin (1), Cilostazol (1), Fasudil Hydrochloride (1), Folfirinox (1) and Lecanemab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Zhejiang Provincial People's Hospital clinical trials